Scarica l'app Stockscreener
21.64
2.32%
0.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Chart based analysis of Travere Therapeutics Inc. trends2025 Geopolitical Influence & Intraday High Probability Alerts - Newser
Identifying reversal signals in Travere Therapeutics Inc.July 2025 Analyst Calls & Advanced Technical Analysis Signals - Newser
Improved Revenues Required Before Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock's 26% Jump Looks Justified - simplywall.st
Is Travere Therapeutics Inc. a good ESG investmentJuly 2025 Setups & Reliable Intraday Trade Alerts - خودرو بانک
Travere Therapeutics Inc. stock trend forecastWeekly Trade Summary & Weekly Hot Stock Watchlists - Newser
How sensitive is Travere Therapeutics Inc. to inflation2025 Analyst Calls & Daily Entry Point Trade Alerts - خودرو بانک
What is Travere Therapeutics Inc.’s book value per share2025 Market Overview & Smart Swing Trading Techniques - خودرو بانک
Can Travere Therapeutics Inc. lead its sector in growthPortfolio Performance Report & Long-Term Capital Growth Ideas - خودرو بانک
Can Travere Therapeutics Inc. rally from current levels2025 Analyst Calls & Smart Allocation Stock Reports - Newser
Does Travere Therapeutics Inc. stock have upside surprise potentialMarket Growth Review & Fast Entry High Yield Tips - خودرو بانک
Travere Therapeutics Inc. recovery potential after sell offJuly 2025 Action & Fast Momentum Stock Entry Tips - Newser
What is the earnings history of Travere Therapeutics Inc.Price Action & Verified Momentum Watchlists - خودرو بانک
Is Travere Therapeutics Inc. trending in predictive chart modelsQuarterly Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Transcript : Travere Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 01 - MarketScreener
Will Travere Therapeutics Inc. continue its uptrendMarket Activity Summary & Daily Momentum Trading Reports - Newser
Technical analysis overview for Travere Therapeutics Inc. stockShort Setup & Accurate Technical Buy Alerts - Newser
Travere Therapeutics' Strategic Momentum in Rare Disease Innovation and Commercial Execution - AInvest
Transcript : Travere Therapeutics, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 02 - MarketScreener
Travere Therapeutics at Cantor Conference: Strategic Insights on FILSPARI By Investing.com - Investing.com Canada
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Price Is Right But Growth Is Lacking - 富途牛牛
Why Travere Therapeutics Inc. is moving todayWeekly Trade Recap & Daily Profit Maximizing Trade Tips - Newser
Travere Therapeutics Inc. stock prediction for this weekPortfolio Growth Summary & Community Supported Trade Ideas - Newser
Can Travere Therapeutics Inc. be the next market leaderWeekly Trade Analysis & Capital Efficient Trade Techniques - خودرو بانک
Is Travere Therapeutics Inc.’s growth already priced inExit Point & AI Forecast for Swing Trade Picks - خودرو بانک
Will Travere Therapeutics Inc. outperform small cap indexes2025 Geopolitical Influence & Safe Entry Zone Identification - خودرو بانک
How to interpret RSI for Travere Therapeutics Inc. stockMarket Trend Review & AI Driven Stock Reports - Newser
Travere Therapeutics shares rise 4.74% intraday after presenting positive long-term data for pegtibatinase at the International Congress of Inborn Errors of Metabolism. - AInvest
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism - Business Wire
Should you hold or exit Travere Therapeutics Inc. now2025 Market Trends & Growth Focused Stock Pick Reports - Newser
Is Travere Therapeutics Inc. stock ready for a breakoutJuly 2025 Review & Expert Approved Momentum Ideas - Newser
Earnings visualization tools for Travere Therapeutics Inc.2025 Stock Rankings & Expert Approved Momentum Ideas - Newser
Statistical indicators supporting Travere Therapeutics Inc.’s strength2025 Buyback Activity & Target Return Focused Picks - Newser
Travere Therapeutics: Strategic Positioning in Renal Disease with Near-Term Catalysts and Valuation Potential - AInvest
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Transcript : Travere Therapeutics, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-02-2025 03 - MarketScreener
Benchmark Reaffirms Buy Rating on Ligand with Raised PT to $175. - AInvest
Risk vs reward if holding onto Travere Therapeutics Inc.Trend Reversal & Consistent Growth Stock Picks - Newser
Is Travere Therapeutics Inc. reversing from oversold territoryJuly 2025 Opening Moves & Consistent Profit Trade Alerts - Newser
Is now the right time to enter Travere Therapeutics Inc.July 2025 Spike Watch & Detailed Earnings Play Alerts - خودرو بانک
How to monitor Travere Therapeutics Inc. with trend dashboardsChart Signals & High Accuracy Swing Trade Signals - Newser
Pullback Watch: Does Travere Therapeutics Inc. have pricing powerJuly 2025 Weekly Recap & Risk Controlled Swing Alerts - خودرو بانک
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):